NEW YORK – The US Patent Trial and Appeal Board has ruled over the last week that all claims of two patents held by 10x Genomics are invalid.
On Jan. 31, the PTAB decided that claims 1 through 26 of US Patent No. 10,240,197 were unpatentable. On Monday, the PTAB ruled that all claims of US Patent No. 10,697,013 were also unpatentable.
The patents had been under scrutiny after Parse Biosciences successfully petitioned for a review of validity as part of its intellectual property battle with 10x. In 2022, 10x sued Parse for patent infringement of three patents, all titled "Methods for analyzing nucleic acids from single cells."
Now, all three patents have been invalidated by the PTAB, "[marking] a significant legal victory," Parse said in a statement. The third patent was invalidated by the PTAB in September, though 10x has said it plans to appeal that decision.
"We respectfully disagree with the PTAB's decision and plan to appeal," a 10x spokesperson said in an email.
"We are pleased with the decision published by the PTAB, further validating Parse's unique position within the single-cell genomics space," Parse CEO and Cofounder Alex Rosenberg said in a statement. "The recent decisions reward innovation and promote accessibility to cutting-edge new tools. This is a win for the research community."